Analys

Sprint Bioscience: Sells TREX1 program to Gilead - Redeye

{newsItem.title}

Redeye Publicerad: 24 Nov 11:05

Sprint Bioscience

Redeye endorses today’s news that Sprint Bioscience has sold its TREX1 program to Gilead Sciences, including an upfront of USD14m, which should ease the financial situation significantly. We provide an initial take.

Länk till analysen i sin helhet: https://www.redeye.se/research/1140433/sprint-bioscience-sells-trex1-program-to-gilead?utm_source=finwire&utm_medium=RSS

Nyheter om Sprint Bioscience

Läses av andra just nu

Om aktien Sprint Bioscience

Senaste nytt